Population pharmacokinetics and exposure –response of selumetinib and its N‐ desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas
ConclusionFindings support continuous selumetinib 25 mg/m2 bid in pediatric patients. Importantly, the updated dosing nomogram ensures that patients will receive a clinically active, yet tolerable, dose regardless of differences in BSA and allows dose reductions, if necessary.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Chemotherapy | Children | Drugs & Pharmacology | Liver | Neurofibromatosis | Neurology | Pediatrics | Urology & Nephrology